What Investors Can Expect from Johnson & Johnson's Earnings Release
What Investors Can Expect from Johnson & Johnson's Earnings Release
Johnson & Johnson (NYSE: JNJ) is gearing up for an important quarterly earnings report. Investors should pay close attention to several key indicators before the announcement.
Analysts' Earnings Forecast
Analysts predict that Johnson & Johnson will report an earnings per share (EPS) of $2.67. This figure serves as a benchmark for investor expectations leading into the report.
The Importance of Guidance
For seasoned and new investors alike, it’s crucial to recognize that stock prices may not merely hinge on whether a company beats or misses earnings estimates. The guidance provided during earnings calls can often have a far more significant impact, shaping market sentiment in the following quarters.
Review of Historical Earnings Performance
In its last quarter, Johnson & Johnson surpassed expectations, achieving an EPS above estimates by $0.17. Following this positive news, the company's shares saw a modest increase of 0.19% the next day. It’s useful to consider the historical performance when predicting future price movements.
Recent Earnings Data
To gain a clearer picture of Johnson & Johnson's financial health, here’s an overview of their recent earnings performance:
Quarterly EPS Estimates and Performance
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | 2.60 | 2.02 | 2.21 | 2.70 |
| EPS Actual | 2.77 | 2.04 | 2.42 | 2.82 |
| Price Change % | 0.0% | 1.0% | 0.0% | -1.0% |
Current Stock Performance
As of a recent trading session, shares of Johnson & Johnson were priced at $156.82. Over the total span of the last year, the stock has seen a slight increase of 0.05%. Such performance can instill confidence in long-term investors as they approach the earnings report with cautious optimism.
Analyst Sentiment
The sentiment surrounding Johnson & Johnson’s stock is monitored closely by analysts. Currently, with seven analyst ratings, the consensus suggests a Neutral rating, translating to an average one-year price target of $169.14, indicating a potential upside of 7.86% for investors.
Peer Analysis
Understanding the competitive landscape is essential for potential investors. Therefore, here’s a quick comparison to key competitors in the industry:
- Merck & Co. shows a Neutral rating with an average one-year price target suggesting a potential downside of approximately 39.1%.
- Pfizer maintains a Neutral consensus, indicating a potential downside of around 84.38%.
- Bristol-Myers Squibb also shows a Neutral trajectory, with a sizable potential downside of 64.93%.
Insightful Peer Comparisons
When diving deeper into the financial metrics of Johnson & Johnson versus its peers, key takeaways emerge:
Consensus and Performance Metrics
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| Johnson & Johnson | Neutral | 2.39% | $14.54B | 14.70% |
| Merck & Co | Neutral | -1.56% | $12.11B | 10.73% |
| Pfizer | Neutral | -7.82% | $10.87B | 3.32% |
| Bristol-Myers Squibb | Neutral | -5.60% | $8.17B | 14.57% |
Key Financial Highlights
Despite some challenges in revenue growth, Johnson & Johnson shows notable strength in areas such as gross profit and return on equity:
- Market Capitalization: The company enjoys a market cap that outstrips industry norms, indicating robust market recognition and size.
- Revenue Growth: Although recent revenue growth is lower compared to competitors, achieving 2.39% signifies a steady climb.
- Net Margin: Johnson & Johnson's net margin stands at an impressive 50.24%, showcasing strong management of costs while maximizing profitability.
- Debt Management: The company’s debt-to-equity ratio is at a favorable 0.67, indicating prudent financial strategies.
About Johnson & Johnson
As the foremost healthcare firm globally, Johnson & Johnson maintains a significant presence, focusing on pharmaceuticals and medical devices. Following the strategic divestment of its consumer division in 2023, the company has concentrated its efforts on high-impact therapeutic areas, ensuring comprehensive growth across various medical domains.
Frequently Asked Questions
When will Johnson & Johnson release its quarterly earnings?
The earnings report is expected this week.
What is the projected earnings per share for Johnson & Johnson?
The consensus estimate for EPS is $2.67.
How did Johnson & Johnson perform last quarter?
The company beat earnings expectations by $0.17 last quarter.
What are the current analyst ratings for Johnson & Johnson?
The current consensus rating is Neutral among analysts.
How does Johnson & Johnson compare to its industry peers?
The company leads in gross profit and return on equity but has lower revenue growth compared to some competitors.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
